Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab

This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.

Participants in the study receive ustekinumab injections as part of routine medical care. The study just observes the efficacy retrospectively and does not interfere with treatment.

Inclusion Criteria:

• Clinical diagnosis of Perianal Fistulizing Crohn's Disease
• Receive ustekinumab therapy

Exclusion Criteria:

• Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
• Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.
• Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.
• Combined with malignant tumor
• Clinical data missing ≥30% or no follow-up